A thorough LC-MS/MS strategy to quantify abaloparatide in rat plasma: method development, validation and application.

Kong Y, Li X, Li Y, Tan Y, Li T, Xiao Y, Zhang L, Yu Q, Rong R

Analytical methods : advancing methods and applications2 Oct 2025

PMID40960186DOI10.1039/d5ay01189bPepBankPUB-40960186

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

01LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In rat plasma analysis, abaloparatide separation on a positively charged surface hybrid column gave reliable chromatography without strong ion-pairing reagents.
In plain wordsIn lab tests, a positively charged column reliably separated abaloparatide without strong ion-pairing reagents.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableChromatographic separation
Study
ratn: not reported in source
rat plasma LC-MS/MS assay
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Plasma samples were purified by protein precipitation, and abaloparatide was then chromatographically separated on a positively charged surface hybrid column, which offered reliable chromatographic results without the addition of any strong ion-pairing reagents.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4096018601
02LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In an LC-MS/MS assay, the selected abaloparatide ion transition was 566.512 to 632.488.
In plain wordsIn lab tests, the assay selected a specific abaloparatide ion transition for detection.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableMass spectrometry ion transition
Study
ratn: not reported in source
rat plasma LC-MS/MS assay
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Ion transitions of m/z 566.512 (7+) → 632.488 for abaloparatide and 687.05 (6+) → 787.26 for the internal standard (teriparatide) were selected for multiple-reaction mass spectrometry detections.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4096018602
03LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In rat plasma, the abaloparatide assay was accurate and precise over 0.02 to 8 ng mL-1.
In plain wordsIn lab tests, the abaloparatide assay was accurate and precise over the reported concentration range.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableValidated quantification range
Study
ratn: not reported in source
rat plasma LC-MS/MS assay
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Validated concentration range
0.02 to 8 ng/mL
rat plasma assay
Source sentences
Summary
The method was validated over a range of 0.02 to 8 ng mL^-1 and was further demonstrated to be accurate and precise.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4096018603
04LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In rat plasma analysis, abaloparatide recovery was 88.7-103%.
In plain wordsIn lab tests, abaloparatide recovery from plasma was 88.7-103%.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableAbaloparatide recovery
Study
ratn: not reported in source
rat plasma LC-MS/MS assay
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Recovery
88.7 to 103%
abaloparatide
Source sentences
Summary
Meanwhile, the method presented acceptable recoveries for abaloparatide (88.7-103%) and the internal standard (102%), and there was no significant matrix effect.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4096018604
05LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In rat plasma analysis, the abaloparatide assay showed no significant matrix effect.
In plain wordsIn lab tests, the abaloparatide assay showed no significant plasma matrix effect.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeMatrix effect
Study
ratn: not reported in source
rat plasma LC-MS/MS assay
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Meanwhile, the method presented acceptable recoveries for abaloparatide (88.7-103%) and the internal standard (102%), and there was no significant matrix effect.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4096018605
06LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In rat plasma, abaloparatide remained stable under the reported refrigerated, frozen-storage and freeze-thaw conditions.
In plain wordsIn lab tests, abaloparatide remained stable under the reported refrigerated, frozen-storage and freeze-thaw conditions.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeStability under handling and storage conditions
Study
ratn: not reported in source
rat plasma LC-MS/MS assay
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Abaloparatide was proved to be stable under the conditions of 4 °C for 2 h at -80 °C for 50 days and three freeze-thaw cycles (-80 °C to 4 °C).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4096018606
07LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In rats, the abaloparatide assay was successfully applied to a pharmacokinetic study after subcutaneous administration.
In plain wordsIn lab tests, the assay successfully measured abaloparatide for a rat pharmacokinetic study after subcutaneous administration.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableApplication to rat pharmacokinetics
Study
ratn: not reported in source
rat plasma LC-MS/MS assay
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
The method was successfully applied to the pharmacokinetic study of abaloparatide in rats after subcutaneous administration.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4096018607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.